Matinas BioPharma Holdings, Inc. (MTNB)
0.8557
-0.07
(-7.69%)
USD |
NYAM |
Nov 17, 16:00
0.8134
-0.04
(-4.94%)
After-Hours: 20:00
Matinas BioPharma Holdings Enterprise Value : -1.040M for Nov. 17, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 17, 2026 | -1.040M |
| November 16, 2026 | -0.962M |
| November 13, 2026 | -0.9917M |
| November 12, 2026 | -0.9715M |
| November 11, 2026 | -0.9587M |
| November 10, 2026 | -0.6286M |
| November 09, 2026 | -0.6176M |
| November 06, 2026 | -0.6726M |
| November 05, 2026 | -0.7057M |
| November 04, 2026 | -0.6726M |
| November 03, 2026 | -0.7277M |
| November 02, 2026 | -0.5626M |
| October 30, 2026 | -0.3205M |
| October 29, 2026 | 0.1086M |
| October 28, 2026 | 0.1196M |
| October 27, 2026 | 0.0315M |
| October 26, 2026 | -0.1555M |
| October 23, 2026 | -0.1108M |
| October 22, 2026 | -0.1005M |
| October 21, 2026 | -0.3095M |
| October 20, 2026 | -0.1115M |
| October 19, 2026 | -0.1555M |
| October 16, 2026 | 0.6257M |
| October 15, 2026 | 0.6807M |
| October 14, 2026 | 0.7467M |
| Date | Value |
|---|---|
| October 13, 2026 | 0.7688M |
| October 12, 2026 | 1.033M |
| October 09, 2026 | 1.176M |
| October 08, 2026 | 1.132M |
| October 07, 2026 | 1.066M |
| October 06, 2026 | 1.330M |
| October 05, 2026 | 1.121M |
| October 02, 2026 | 0.9228M |
| October 01, 2026 | 0.6807M |
| September 30, 2026 | 0.8238M |
| September 29, 2026 | 0.425M |
| September 28, 2026 | 0.2756M |
| September 25, 2026 | 0.22M |
| September 24, 2026 | 0.3354M |
| September 23, 2026 | 0.3161M |
| September 22, 2026 | 0.3289M |
| September 21, 2026 | 0.3091M |
| September 18, 2026 | 0.2226M |
| September 17, 2026 | 0.2393M |
| September 16, 2026 | 0.2527M |
| September 15, 2026 | 0.22M |
| September 14, 2026 | 0.425M |
| September 11, 2026 | 0.3802M |
| September 10, 2026 | 0.5083M |
| September 09, 2026 | 0.3719M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.261B |
| Alnylam Pharmaceuticals, Inc. | 20.36B |
| Anika Therapeutics, Inc. | 153.30M |
| Savara, Inc. | 821.52M |
| Arrowhead Pharmaceuticals, Inc. | 6.282B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.514M |
| Total Expenses (Quarterly) | 6.514M |
| EPS Diluted (Quarterly) | -9.348 |
| Earnings Yield | -2.50K% |
| Normalized Earnings Yield | -2574.56 |